Assessment of COVID‐19 Vaccine Impact on Women’s Menstrual Health within an 18‐Month Follow‐Up DOI Creative Commons
Mona Sadat Larijani, Sana Eybpoosh, Delaram Doroud

и другие.

Obstetrics and Gynecology International, Год журнала: 2024, Номер 2024(1)

Опубликована: Янв. 1, 2024

Considering menstruation as a crucial factor in females' health and fertility, any that could change its cycle is important. This study was conducted from April 2021 to October 2022 on females who got 3 doses of vaccines against SARS-CoV-2 through different platforms. The participants were requested provide the trained experts with changes regarding menstrual cycles after each dose vaccine up 6 months booster shots. disturbances related identified by adverse events committee find possible associations applied vaccines. Of 308 women participated until end study, 22 (7.1%) complained about at least one abnormality their patterns. most common disturbance metrorrhagia 10 (48%) incidences followed menorrhagia (24.2%). Notably, complaints persistent 59% patients. In addition, 14 studied cases developed COVID-19 infection disorders. these cases, also play role persistence postvaccine disturbances. vaccination affect no remarkable previous medical history. More longitudinal studies are required this issue.

Язык: Английский

Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine DOI Creative Commons
Behrokh Farahmand, Mona Sadat Larijani, Fatemeh Fotouhi

и другие.

Heliyon, Год журнала: 2023, Номер 9(10), С. e20555 - e20555

Опубликована: Сен. 29, 2023

COVID-19 pandemic has been managed through global vaccination programs. However, the antibody waning in various types of vaccines came to notice. Hereby, PastoCovac Plus as a protein subunit vaccine was investigated immunized health care workers by COVAXIN (BBV152). The booster recommended at least three months post second dose COVAXIN. Sera collection done before and after each injection. SARS-CoV-2 PCR test monthly detect any asymptomatic symptomatic breakthrough. 47.9 24.3% participants were seronegative for anti-N anti-S antibodies COVAXIN, respectively. On average, fold-rises 70, 93, 8 mean-rises 23.32, 892.4, 5.59 recorded regarding neutralizing antibody, quantitative semi-quantitative anti-Spike Anti-Spike seroconversion seen 59.3% 45.7%, breakthrough assessment showed that all isolated samples belonged Delta variant. boosting is strongly combination with inactivated platforms against SARS-CoV-2.

Язык: Английский

Процитировано

11
Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals DOI Creative Commons
Sana Eybpoosh,

Alireza Biglari,

Rahim Sorouri

и другие.

PLoS Pathogens, Год журнала: 2023, Номер 19(11), С. e1011744 - e1011744

Опубликована: Ноя. 1, 2023

Background This study aimed at evaluation and comparison of PastoCovac Plus protein-subunit vaccine in parallel with ChAdOx1-S (AstraZeneca) BBIBP-CorV (Sinopharm) primarily vaccinated volunteers two doses or BBIBP-CorV. Materials methods 194 enrolled the who were previously primed 2 vaccines. They divided into heterologous regimens receiving a third dose Plus, homologous groups ChAdOx1-S. Serum samples obtained just before 4 weeks after booster dose. Anti-spike IgG neutralizing antibodies quantified conventional live-virus neutralization titer, (cVNT50) assay was done against Omicron BA.5 variant. Moreover, adverse events data recorded doses. Results ChAdOx1-S/PastoCovac group reached 73.0 units increase anti-Spike rise compared to ChAdOx1-S/ ( P : 0.016). No significant difference observed between regarding antibody 0.256), indicating equivalency both types. Adjusting for baseline titers, BBIBP-CorV/PastoCovac showed 135.2 <0.0001) IgG, 3.1 0.008) unit mean group. Adjustment COVID-19 history, age, underlying diseases, titers increased odds fourfold (OR: 1.9; 0.199) BBIBP CorV 37.3; < 0.0001) their corresponding arms. The rise, adjustment same variables, 2.4 0.610) 5.4 0.286) groups. All types had potency neutralize variant no difference. highest rate event incidence Conclusions application individuals successfully specific antibodies’ levels without any serious events. could be administrated regimen effectively boost humoral immune responses.

Язык: Английский

Процитировано

11
Determination of COVID-19 Late Disorders as Possible Long-COVID and/or Vaccination Consequences DOI Creative Commons

Mona Sadat Larijani,

Anahita Bavand,

Mohammad Banifazl

и другие.

Journal of Primary Care & Community Health, Год журнала: 2024, Номер 15

Опубликована: Янв. 1, 2024

In this era in which the vast majority of global population have developed COVID-19 infection and/or got vaccinated against it, identification late disorders as vaccines’ side effect or long-COVID manifestation seems essential. This study included individuals 4 different vaccine regimens including inactivated virus-based, subunit protein, and adenovirus-based vaccines a follow-up schedule 6-month post booster shot. All documented adverse events were thoroughly assessed considering cases’ medical history by Adverse Events Committee Pasteur Institute Iran. Totally 329 who 3 doses vaccination followed 6 months after shots among whom 41 (12.4%) cases with mean age 40.9 ± 10.48 years had type disorder. Gynecological osteoarticular involvements most common recorded 73.1% possibly linked to outcomes rest affected both long-COVID-19 vaccination. Notably, average time symptoms persistence was 155 10.4 days. has advantage long-term presents various forms each episode About 26.8% people persistent complications suffered from long-COVOD/ differentiation between quite challenging. Long-term studies large essential outline role regarding complications.

Язык: Английский

Процитировано

3
Lessons from COVID-19 Pandemic: A Successful Policy and Practice by Pasteur Institute of Iran DOI Creative Commons
Mona Sadat Larijani, Alireza Biglari, Rahim Sorouri

и другие.

Deleted Journal, Год журнала: 2024, Номер 28(1), С. 1 - 7

Опубликована: Янв. 1, 2024

The present study aims to provide an insight the comprehensive efforts of PII regarding COVID-19 management, research, achievements, and vaccine production, though there are many challenges.The relevant literature review was investigated through national international database also reports from related research departments.Six strategies were taken by manage pandemic COVID-19.While this has been hopefully controlled, SARS-CoV-2 could still be a potential threat.Therefore, data management updated studies, as well longterm safety efficacy vaccines on agenda.

Язык: Английский

Процитировано

1
Long-term rheumatoid manifestations as a consequence of COVID-19 and/or vaccination: A case report after a 2-year follow-up DOI Creative Commons

Mona Sadat Larijani,

Mohammad Banifazl,

Afsaneh Karami

и другие.

Heliyon, Год журнала: 2024, Номер 10(3), С. e24982 - e24982

Опубликована: Янв. 18, 2024

COVID-19 is now established as a multi-organ involvement disease with broad range of manifestations. Identification post-acute incidence critical according to increasing number late symptoms reports. Hereby, we report case past history who presented different manifestations including osteoarticular and neurological within long-term follow-up. The organs initiated lately after primary vaccinations (with inactivated vaccine) lasted few months without any pre-existing medical condition. However, upon the completion vaccine schedule receiving protein subunit vaccine, PastoCovac Plus, booster, improved substantially resolved, though in reinfection episode partial, reoccurrence was recorded. This presentation can be challenging issue owing fact that majority global population are vaccinated also experience this era sometimes differentiation between consequences virus post or vaccination side effects difficult.

Язык: Английский

Процитировано

1
Adverse effects of COVID-19 vaccine in the paediatric population: a focus on the cardiovascular system DOI Creative Commons
Ghena Lababidi, Hossam Lababidi, Fadi Bitar

и другие.

Cardiology in the Young, Год журнала: 2024, Номер unknown, С. 1 - 9

Опубликована: Дек. 5, 2024

Abstract The COVID-19 pandemic had an unprecedented impact on healthcare systems and exists globally. To control progression, vaccines were developed licensed for use in the adult population early 2021 became available paediatric cohorts several months later. Since then, studies have reported adverse events severe cohorts. question remains whether there a significant risk to vaccination. This study reviews classification presentation of discusses relevant reports literature. An emphasis is put cardiovascular events. paper also provides current future perspectives relative pandemic, its control, vaccine immunology.

Язык: Английский

Процитировано

1
Assessment of COVID‐19 Vaccine Impact on Women’s Menstrual Health within an 18‐Month Follow‐Up DOI Creative Commons
Mona Sadat Larijani, Sana Eybpoosh, Delaram Doroud

и другие.

Obstetrics and Gynecology International, Год журнала: 2024, Номер 2024(1)

Опубликована: Янв. 1, 2024

Considering menstruation as a crucial factor in females' health and fertility, any that could change its cycle is important. This study was conducted from April 2021 to October 2022 on females who got 3 doses of vaccines against SARS-CoV-2 through different platforms. The participants were requested provide the trained experts with changes regarding menstrual cycles after each dose vaccine up 6 months booster shots. disturbances related identified by adverse events committee find possible associations applied vaccines. Of 308 women participated until end study, 22 (7.1%) complained about at least one abnormality their patterns. most common disturbance metrorrhagia 10 (48%) incidences followed menorrhagia (24.2%). Notably, complaints persistent 59% patients. In addition, 14 studied cases developed COVID-19 infection disorders. these cases, also play role persistence postvaccine disturbances. vaccination affect no remarkable previous medical history. More longitudinal studies are required this issue.

Язык: Английский

Процитировано

0